APA (7th ed.) Citation

Oh, J., Huh, K. Y., Cho, Y., Cha, J., Kim, S., Yoon, S. H., . . . Lee, H. (2020). Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc‐fused interleukin‐1 receptor antagonist, in healthy subjects: A first‐in‐human study. British journal of clinical pharmacology, 86(2), 372-379. https://doi.org/10.1111/bcp.14161

Chicago Style (17th ed.) Citation

Oh, Jaeseong, et al. "Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of HL2351, a Novel Hybrid Fc‐fused Interleukin‐1 Receptor Antagonist, in Healthy Subjects: A First‐in‐human Study." British Journal of Clinical Pharmacology 86, no. 2 (2020): 372-379. https://doi.org/10.1111/bcp.14161.

MLA (9th ed.) Citation

Oh, Jaeseong, et al. "Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of HL2351, a Novel Hybrid Fc‐fused Interleukin‐1 Receptor Antagonist, in Healthy Subjects: A First‐in‐human Study." British Journal of Clinical Pharmacology, vol. 86, no. 2, 2020, pp. 372-379, https://doi.org/10.1111/bcp.14161.